Recombinant Growth Hormone for Nephropathic Cystinosis
Growth hormone therapy should be considered at all stages of CKD in children with nephropathic cystinosis who have persistent growth failure (height <3rd percentile and height velocity <25th percentile), making it a unique exception to the usual CKD stage 3-5 requirement for rhGH treatment. 1
Why Cystinosis is Different
Children with nephropathic cystinosis experience severe growth failure in early life despite only mild reductions in GFR, primarily due to renal Fanconi syndrome rather than advanced kidney disease itself. 1 This distinguishes them from other CKD patients and justifies earlier intervention.
Evidence Quality and Strength
The 2019 Nature Reviews Nephrology guidelines provide a Grade C, moderate recommendation specifically for cystinosis patients at all CKD stages. 1 While this is lower than the Grade B recommendation for CKD stages 3-5, it reflects the limited RCT data available—most evidence comes from uncontrolled studies showing increased growth rates over 3 years with superior growth responses compared to baseline. 1
Treatment Criteria
Initiate rhGH when:
- Height is below the 3rd percentile for age and sex, AND
- Height velocity is below the 25th percentile
- Other treatable causes of growth failure have been addressed
- Growth potential remains (open epiphyses)
- Patient is >6 months old
Critical distinction: Unlike other CKD patients who require stage 3-5 disease, cystinosis patients qualify at any CKD stage, including stages 1-2. 1
Supporting Research Evidence
A 2012 study demonstrated that rhGH significantly improved growth in cystinosis patients, with final height above -2 SDS in 6 of 7 treated patients, while 2 untreated patients remained below -4 SDS despite cysteamine therapy. 2 The authors concluded rhGH should be initiated early in life.
Long-term safety data (up to 5 years) shows no acceleration of renal function deterioration with rhGH treatment, whether or not patients receive concomitant cysteamine. 3 This addresses a key safety concern and justifies continued treatment.
Important Caveats
Absolute Contraindications
Do not start rhGH in patients with:
- Closed epiphyses
- Active malignancy
- Acute critical illness
- Severe secondary hyperparathyroidism (PTH >500 pg/ml)
- Proliferative or severe non-proliferative diabetic retinopathy
- During the first year after kidney transplantation
Clinical Pitfalls
Cysteamine alone is insufficient: Growth retardation in cystinosis is more pronounced than in other CKD conditions and is mostly not corrected by cysteamine therapy alone. 2 Don't delay rhGH while waiting for cysteamine to improve growth.
Body composition changes: Recent data shows cystinosis patients develop unique changes in body proportions and fat stores distinct from other CKD patients, with progressive decrease in upper arm fat area reaching -0.8 z-score in adolescence. 4 This suggests factors beyond CKD contribute to growth impairment.
Timing matters: The evidence suggests earlier initiation yields better outcomes. Patients not treated with rhGH may have final heights below -4 SDS despite cysteamine started in early childhood. 2
Treatment Response
Expect cumulative height increases of 1.1-1.9 SDS over 5-6 years in prepubertal children with CKD. 1 Growth response is positively associated with residual renal function, target height, initial target height deficit, and treatment duration, but negatively associated with older age at treatment start. 1
Practical point: Discuss pros and cons with families before initiating treatment, particularly important for patients with syndromic kidney diseases like cystinosis. 1